Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 228 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Clarke R, Bennett D. Folate and prevention of neural tube defects. BMJ 2014;349:g4810. [Ref.ID 98164]
2. Cita con resumen
Pastemak B, Svanström H, Molgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA 2013;310:1601-11. [Ref.ID 96391]
4.Tiene citas relacionadas Cita con resumen
Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strenghts of the disproportionality analysis of identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011;72:905-8. [Ref.ID 91873]
6.Tiene citas relacionadas Cita con resumen
Mitchell AA. Fetal risk from ACE inhibitors in the first trimester. BMJ 2011;343:857-8. [Ref.ID 91753]
7. Cita con resumen
Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medications use during pregnancy and risk of birth defects. National Birth Defects Prevention Study. Arch Pediatr Adolesc Med 2009;163:978-85. [Ref.ID 86933]
8.Tiene citas relacionadas Cita con resumen
9.Tiene citas relacionadas
Gardiner HM, Fouron JC. Folic acid fortification and congenital heart disease. BMJ 2009;338:1221-2. [Ref.ID 85956]
11.Tiene citas relacionadas
U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation Statement. Ann Intern Med 2009;150:626-31. [Ref.ID 85876]
12.
De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, Fernández B, Lee NS, Niyonsenga T. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007;357:135-42. [Ref.ID 80552]
13. Cita con resumen
Santos LMP, Pereira MZ. The effect of folic acid fortification on the reduction of neural tube defects. Cad Saude Publica 2007;23:17-24. [Ref.ID 80453]
14.
Anónimo. Prévention des anomalies de fermeture du tube neural. Prescrire 2007;27:454-7. [Ref.ID 80262]
15.
Martínez-Frías ML, Grupo de Trabajo del ECEMC. Adecuación de las dosis de ácido fólico en la prevención de defectos congénitos. Med Clin (Barc) 2007;128:609-16. [Ref.ID 80011]
16. Cita con resumen
Anónimo. Vitamin supplements. Med Lett Drugs Ther 2005;47:57-8. [Ref.ID 76848]
17.
Tanne JH. US study shows that folic acid decreases neural tube defects. BMJ 2005;331:594. [Ref.ID 74807]
18.Tiene citas relacionadas
Busby A, Abramsky L, Dolk H, Armstrong B, a Eurocat Folic Acid Working Group. Preventing neural tube defects in Europe: population based study. BMJ 2005;330:574-5. [Ref.ID 73110]
19.Tiene citas relacionadas
Botto LD, Lisi A, Robert-Gnansia E, Erickson JD, Vollset SE, Mastroiacovo P, Botting B, Cocchi G, De Vigan C, de Walle H, Feijoo M, Irgens LM, McDonnell B, Merlob P, Ritvanen A, Scarano G, Siffel C, Metneki J, Stoll C, Smithells R, Goujard J. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working?. BMJ 2005;330:571-3. [Ref.ID 73109]
20.
Kirke PN, Mills JL, Molloy AM, Brody LC, O'Leary VB, Daly L, Murray S, Conley M, Mayne PD, Smith O, Scott JM. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ 2004;328:1535-6. [Ref.ID 70544]
Seleccionar todas
 
 1 a 20 de 228 siguiente >>